Dw News
@dwnews·6.3M subscribers·48.6K videos
US drugmaker: Alzheimer's development can be slowed down | DW News
Posted
July 17, 2023
Views
11,417
Likes
242
Comments
41
Engagement
2.48%
July 17, 2023
11,417
242
41
2.48%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
6:59Now PlayingUS drugmaker Eli Lilly says its experimental drug Alzheimer's drug Donanemab can slow down the development of the disease. Patients with the disease will inevitably deteriorate, but the company says that process can be delayed by four to seven months.
Eli Lilly wants the Federal Drugs Administration to approve its product. The FDA turned down a request for early approval earlier this year and demanded further trials. The company say those trials show the drug slows the development of Alzheimers in 60% of early stage patients, but also reported significant side-effects.
For more on this, we talk to Eric Widera. He's professor of Medicine and clinician-educator in the Division of Geriatrics at the University of California in San Francisco. He also wrote an editorial published alongside that Eli Lilly report in the Journal of the American Medical Association today.
#alzheimer #usa #dementia
For more news go to
Follow DW on social media:
Für Videos in deutscher Sprache besuchen Sie
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
